difference between the NLR measurements of the cases from different groups (p<0.001).  

**Conclusion** As a non-specific inflammatory marker, NLR was elevated in women with endometrial cancer. Simple, cheap and easy-to-perform, the NLR can be used as a potential inflammatory marker, for endometrial malignancy.

**2022-RA-1017-ESGO**  
**CONCURRENT ENDOMETRIAL CARCINOMA IN HYSTERECTOMY SPECIMENS IN PATIENTS WITH ATYPICAL ENDOMETRIAL HYPERPLASIA**

1. Cemal Resat Atalay, 2Funda Atalay. 1Gynecology and Obstetrics, ANKARA CITY HOSPITAL Ankara Numune Education and Research Hospital, ANKARA, Turkey; 2Dr.AY Ankara Oncology Education and Research Hospital, ANKARA, Turkey

10.1136/ijgc-2022-ESGO.280

**Introduction/Background** The aim of this study was to evaluate the role of sub-histological types of atypical endometrial hyperplasia in the patient group treated with the diagnosis of atypical endometrial hyperplasia and whose final pathology is endometrial cancer.

**Methodology** A retrospective review of five years of patients (N = 94) who underwent hysterectomy for a diagnosis of atypical endometrial hyperplasia at a tertiary gynaecologic oncology center. Clinical and pathological characteristics were obtained.

**Results** The rate of concurrent endometrial carcinoma was 40.34% (n = 23) with most being stage 1A endometrioid histology. Significantly higher rates of carcinoma were reported in patients with complex atypical hyperplasia (86.95%) and EIN (13.04%). There was no patient who had simple atypia hyperplasia but whose pathology was endometrial cancer after hysterectomy.

**Conclusion** Complex atypical hyperplasia/EIN and postmenopausal status were significant predictors of concurrent endometrial carcinoma in patients with atypical endometrial hyperplasia.

**2022-RA-1019-ESGO**  
**ENDOMETRIAL HYPERPLASIA AND CANCER: RESULTS OF TWO REFERENCE HOSPITALS IN ANKARA**

1. Funda Atalay, 2Cemal Resat Atalay, 1Hacer Ozdemir. 1Gynecologic Oncology Surgery, Dr. AY Ankara Oncology Education and Research Hospital, Ankara, Turkey; 2Gynecology and Obstetrics, ANKARA CITY HOSPITAL (Ankara Numune Education and Research Hospital), ANKARA, Turkey

10.1136/ijgc-2022-ESGO.281

**Introduction/Background** Endometrial hyperplasia (EH) was classified by the World Health Organization in 2014 into two categories based on the presence of cytological atypia. Approximately, 200,000 new cases of EH are diagnosed annually in developed countries. EH is of significant clinical importance, given that it is the precursor of endometrial carcinoma, the most common gynecological cancer in developed countries.

**Methodology** We retrospectively reviewed the medical records of 675 cases with pathology results of nonatypical endometrial hyperplasia and above, out of 1122 patients who underwent endometrial biopsy for abnormal uterine bleeding at two referral hospitals in Ankara between 2015 and 2020. Data were extracted for age, menopausal status, endometrial thickness, presence of breast cancer, use of tamoxifen, symptoms, surgical treatment and histopathology.

**Results** Data of 675 patients were evaluated. The median age was 47 years (min 24-max 82). Transvaginal ultrasonography results of 530 patients were obtained, median endometrial thickness was 12 mm (min 3-max 40). 526 of the cases were premenopausal, 149 of them were postmenopausal. 12 of 23 cases with breast cancer were using tamoxifen. 32 of 675 cases were asymptomatic, 496 of them were abnormal uterine bleeding, and 143 of them had endometrial biopsy with the diagnosis of postmenopausal bleeding. 164 of the cases were treated surgically.

**Conclusion** In the evaluation of 1122 patients who underwent endometrial biopsy due to abnormal uterine bleeding, endometrial hyperplasia and higher lesions were detected in 675 (60.16%) cases, and endometrial cancer was observed in 86 (7.66%) of these cases.

**2022-VA-1045-ESGO**  
**SENTINEL LYMPH NODE BIOPSY IN SURGICAL STAGING FOR ENDOMETRIAL CARCINOMA PATIENTS**

Laura Gil Garcia, Ana Pérez-Cejuela, Alejandro Muller Bravo, Marina Pérez Duce, Patryk Daniel Janiszewski, Maria De Cardenas Carrillo de Albornoz, Ana Maria Granado San Miguel, Jose Antonio Mestanza Garrido. Hospital General Universitario de Talavera de la Reina, Talavera de la Reina, Spain

10.1136/ijgc-2022-ESGO.282

**Introduction/Background** Sentinel lymph node mapping (SLN) has emerged as a reliable alternative for endometrial cancer (EC) lymph node assessment. Numerous studies have shown that SLN is comparable to LND in both low- and high-risk EC patients, and that oncological outcomes are similar between the SLN and LND groups (1, 2). The 2020 National Comprehensive Cancer Network guidelines (3) recommend surgical staging in low- and high-risk EC patients. The advantage of SLN lies in pathological superstaging, avoiding overtreatment and undertreatment.

We did retrospective single-center study, to evaluate the detection rate and diagnostic accuracy of the SLN procedure in predicting pathological iliac lymph node status in patients with early-stage endometrial cancer from 1 April 2020 to 1 February 2022.

**Methodology** SLN assessment using cervical injection with green indocyanine administered to the cervix (superficial 1–2 cm, deep 1–3 mm, 4 ml in total) and systematic dissection of pelvic lymph nodes in patients with FIGO stage I-II endometrial cancer. All lymph nodes were histopathologically examined, and SLNs were serially negative predictive value (NPV) of sentinel lymph node biopsy.

**Results** Overall, 22 patients, SLN group (21, 95%), and LND group (11, 50%) allowing us to correlate the results of both techniques. SLN were positive in 6 cases (28.5%), and LND in 13 cases (62.5%) with most being stage 1A endometrioid histology. SLN were positive in 6 cases (28.5%) and LND positive in 80% of cases. SLN mapping showed high sensitivity of 100% and negative predictive value of 100%, in our results.

Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504 A131
Conclusion Restaging with lymphadenectomy does not alter prognosis of early-stage, LVI+ positive patients.

**2022-RA-1052-ESGO**

**LOW-RISK ENDOMETRIAL CANCER AND NO ADJUVANT TREATMENT: DO ISOLATED TUMOR CELLS (ITC) HAVE AN EFFECT ON RECURRENCE? AN INTERNATIONAL MULTI-INSTITUTIONAL COMPARATIVE STUDY BETWEEN ITC AND NODE-NEGATIVE IN SENTINEL LYMPH NODE BIOPSY**

1. Giuseppe Cucinella, 2,1,3 Gabriella Schiavari, 2,1,3 Xuin Clare Zhou, 1,2 Mariam Alhilli, 2 Sumer Wallace, 2,1,3 Christoph Wohlmut, 2,1,3 klaudio Baoicol, 1,2 Nedim Tokgozgozlu, 1,2 Francesco Raspaigioni, 1,2 Alessandro Buda, 1,2 Yarina Zanagoloto, 1,3 Ignazio Zapedarel, 1,3 Nisha Jagasia, 1,3 Robert Gianotti II, 1,3 Ariel Glickman, 1,3 Michele Peiretti, 1,3 Maximilian immer, 1,3 Enrique Chacon, 2,1,3 Julian Di Guelmi, 2,1,3 Saverio Pereira, 2,1,3 Enora Laas, 2,1 Armi Fishman, 2,1 Caroline C. Nitschmann, 2,1 Katherine Kunirt, 4,1,3 Kristen Moriarty, 5,1 Amy Joehlin-Price, 6,1,3 Brittany Lees, 7,1,3 Alanov Cevens, 6,1,3 Louise de Brot, 6,1,3 Cagatay Taskiran, 5,1 Giorgio Bogani, 5,1 Tommaso Grassi, 5,1 Cristina Paniga, 5,1 Francesco Multini, 5,1 Alicia Hernandez-Gutierrez, 5,1 Spyridon Mastroyannis, 5,1 Vito Chiantera, 5,1 Amy L. Weaver, 5,1 Michelle E. McGree, 5,1 Andrea Mariani, 5,1 Gretchen Glaser, 5,1 Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN; 2,1,3 Department of Gynecologic Oncology, University of Palermo, Palermo, Italy; 2,1,3 European Institute of Oncology IRCCS, Milan, Italy; 2,1,3 Hartford HealthCare, Hartford, CT; 2,1,3 Cleveland Clinic, Cleveland, OH; 2,1,3 University of Wisconsin School of Medicine and Public Health, Madison, WI; 2,1,3 Sunnybrook Health Sciences University, Toronto, Ontario, ON, Canada; 2,1,3 Department of Obstetrics and Gynecology, Kardec Medical University, Salzburg, Austria; 2,1,3 A.C. Camargo Cancer Center, Sao Paulo, Brazil; 2,1,3 Turkish Society of Gynecologic Oncology, Istanbul, Turkey; 2,1,3 Fondazione IRCCS Istituto Nazionale Tumori -Milan, Milan, Italy; 2,1,3 University of Milano-Bicocca, Monza, Italy; 2,1,3 Ferreiro Hospital, Verduro, Italy; 2,1,3 La Paz University Hospital-IDPAZ, Madrid, Spain; 2,1,3 Mater Hospital Brisbane and Mater Research Institute, University of Queensland, Brisbane, Australia; 2,1,3 University of Pennsylvania Health System, Philadelphia, PA; 2,1,3 Barcelona Clinic Hospital, Barcelona, Spain; 2,1,3 University of Cagliari, Cagliari, Italy; 2,1,3 Department of Gynecology, Medical University of Graz, Graz, Austria; 2,1,3 Clinica Universidad de Navarra, Madrid, Spain; 2,1,3 Hospital Britanico de Buenos Aires, Buenos Aires, Argentina; 2,1,3 Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain; 2,1,3 Cote University, Paris, France; 2,1,3 Meir Medical Center, Faculty of Medicine, Tel-Aviv University, Israel; 2,1,3 Lahey Clinic, Burlington, MA; 2,1,3 University of Chicago, Chicago, IL; 2,1,3 Obstetrics and Gynecology Residency Program, Wayne University, Michigan; 2,1,3 Department of Gynecologic Oncology, Koc University School of Medicine, Istanbul, Turkey; 2,1,3 San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; 2,1,3 Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

10.1136/ijgc-2022-ESGO.284

Introduction/Background The prognostic value of isolated tumor cells (ITC) (≤0.2 mm) in sentinel lymph nodes (SLN) of patients with endometrial cancer (EC) is still unclear. This study compared the recurrence-free survival (RFS) of low-risk EC patients who received no adjuvant therapy, who underwent a SLN biopsy and were node-negative vs. those who had ITC.

Methodology Patients with SLN-ITC, between 2012 and 2019, were identified from 21 centers worldwide, while SLN-node-negative patients were identified from Mayo Clinic, Rochester, between 2013 and 2018 and served as a comparing group. Only patients with stage IA endometrioid histology, and low-risk profile (grade 1 or 2 endometroid and myometrial infiltration ≤50%) who did not receive adjuvant therapy were included. The primary outcome was non-vaginal recurrence (peritoneal, hematogenous, and lymphatic).

Results A total of 494 patients (42 ITC and 452 node-negative) were included. There were 15 recurrences and the overall median follow-up for patients without recurrence was 2.2 (IQR 1.1–3.0) years for the ITC group and 2.6 (IQR 0.6–4.2) years for the node-negative group. The presence of SLN-ITC...